Business Model Breakdown
How Precision Optics Corporation Inc Makes Money
POCI
Market Cap
$63M
Annual Revenue
$9M
Profit Margin
-17.0%
The Short Version
Precision Optics designs and manufactures highly specialized optical instruments and components, primarily for the medical and defense/aerospace industries. They create custom imaging systems, micro medical cameras (including 3D endoscopes), and illumination products that require extreme precision and miniaturization. The company generates revenue by selling these advanced optical solutions and through engineering services for product development, serving customers who need highly customized, high-performance optics that general manufacturers cannot provide.
Where the Revenue Comes From
Production Revenue (~87% of Q3 FY2026 revenue)
Engineering Revenue (~13% of Q3 FY2026 revenue)
Who buys: Medical device manufacturers, defense contractors, and aerospace companies requiring custom optical solutions.
Why It Works (Competitive Advantages)
- ✔Specialized expertise in micro-optics and miniature cameras for medical and defense.
- ✔Custom design and manufacturing capabilities, allowing for high-value contracts.
- ✔Strong relationships in the medical and defense industries, evidenced by consistent demand.
Economic Moat: Narrow (Intangible Assets/IP (specialized optical designs, micro-camera technology), Switching Costs (custom integrated solutions make it difficult for customers to switch suppliers), Cost Advantages (potential in specialized manufacturing processes))
What Our Analysis Says
DVR Score as of June 3, 2026
Precision Optics (POCI) continues to demonstrate exceptional operational momentum, evidenced by a 108% YoY revenue surge in Q3 FY2026 to $8.7 million and a raised FY2026 revenue guidance to $29-31 million. The significant narrowing of net loss to $0.1 million and positive Adjusted EBITDA of $0.3 million signal a clearer path to profitability and improved operational efficiency. The previous institutional interest from Needham (15.3% stake) and an oversubscribed $10.6 million equity offering underscore market confidence and bolstered liquidity. However, the persistent concern regarding the company's ability to meet its debt service coverage ratio in fiscal 2026 remains a notable financial risk, tempering the overall score despite the strong operational turnaround. The 10x potential rests on continued execution in specialized medical/defense optics and successful debt management.